Blog

SC pembrolizumab demonstrated noninferiority compared with IV pembrolizumab in the phase III MK-3475A-D77 trial – ESMO

European Society for Medical Oncology/LinkedIn

Mar 27, 2025, 14:45

SC pembrolizumab demonstrated noninferiority compared with IV pembrolizumab in the phase III MK-3475A-D77 trial – ESMO

ESMO – European Society for Medical Oncology shared a post on LinkedIn:

“As presented at ELCC25, subcutaneous (SC) pembrolizumab – consisting of pembrolizumab co-formulated with berahyaluronidase alfa – demonstrated noninferiority in pharmacokinetics compared with intravenous (IV) pembrolizumab in the phase III MK-3475A-D77 trial. Similar efficacy outcomes were observed.

Patients may prefer SC immunotherapy administration and other potential benefits include reductions in pharmacy preparation, nursing administration time, infusion-chair occupancy and infusion-related adverse events than with IV administration.

Results plus commentary in the ESMO Daily Reporter.”

berahyaluronidase alfa cancer ELCC25 ESMO ESMODailyReporter European Society for Medical Oncology fight against cancer Global fight against cancer IV MK-3475A-D77 trial OncoDaily Oncology pembrolizumab Subcutaneous pembrolizumab

BEATcc Trial at ESMOGynaec25: Atezolizumab Benefits Cervical Cancer Patients Regardless of PD-L1 Status

15 Posts Not to Miss from EACR 2025

ASCO 2025 RCC Advances: Expert Insights by Ilya Tsimafeyeu

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself